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ABSTRACT
Pharmacovigilance is concerned with the
detection, assessment, understanding, and
prevention of adverse reactions to medicines.
It is helpful to prevent undesired harm
sustained by the patient due to inappropriate
or unsafe use of medicinal agents. As the use of
drugs and polypharmacy increase in prevalence,
pharmacovigilance gains relevance and
momentum. Practice-based research networks
have the potential to enhance health research
by promoting earlier detection of adverse events
at a decreased level of cost. This article explores
the recent evidence of an improved benefit of
administering non-steroidal antiinflammatory
drugs (NSAIDs) in the fasting state, and authors
propose that an improved pharmacovigilance
system is both needed and feasible provided
records are adapted to a nationwide integration
of pharmacoepidemiology data.
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The concern for quality of care and
sustainability of the health system has been
one of the top priorities for health policy during
the last decade. The relevance of primary health
care in a health system is now unquestionable
and its pivotal role indisputable. The
Patient-Centered Medical Home initiative is
one recent example of this [1]. However, its
importance is not restricted to clinical care, but
should also be extended to clinical research [2].
As it is well known, research is needed to
improve the quality of care provided, both in
the present (Are we delivering state-of-the-art
care?) and into the future (How can we improve
state-of-the-art clinical practice?). Indeed, quality
of care is more about implementing an
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operative learning system inside an institution
than implementing someone else’s lessons [3].
Therefore, the focus on quality care requires
promoting research, as current standards of care
are far from optimal. One example of this comes
from a recent systematic review comparing oral
analgesics in fed and fasting states [4]. The fed
state reduced maximum plasma concentration
of acetylsalicylic acid, ibuprofen, diclofenac,
and acetaminophen (paracetamol) from 15 to
56 % of the corresponding fasting maximum
concentration. Accordingly, time to maximum
plasma concentration was also increased in the
fed state (from 1.30 to 2.80 times longer than in
the fasting state) for those same analgesic drugs.
These pharmacokinetic differences are expected
to impact therapeutic efficacy. If high-quality
large-scale evidence were available on the
efficiency of analgesic drugs for patients taking
them in different conditions (namely fasted and
fed states), this could have been suspected and
investigated earlier.
Pharmacological relief of pain is one of the
most illustrative examples of how medicine as a
discipline came to improve human suffering.
Empathy to those in pain and the inquisitive
spirit have been the founding stones for the
building of knowledge on the physiological
phenomena underlying pain sensation and its
pharmacological control. This (so far
unfinished) body of expertise is responsible for
one of the most important contributions of
medicine to human existence: the relief of
painful experiences. Since the public
demonstration of analgesia in a medical
context (at the Ether Dome, Massachusetts
General Hospital, Boston) in 1846 by William
T.G. Morton with diethyl ether, innumerous
other substances have been developed and used
in the control of painful sensations. Whether it
is in the trauma context, in the operating room,
or during the exacerbation of chronic back pain,
just to name a few, pharmacological pain
control is mandatory and its absence is
carelessness. Not surprisingly, analgesics are
the most prescribed categories of drugs by far
[5]. There have been international guidelines for
several decades and the analgesic ladder is
deeply rooted in the prescribing rationale of
every practitioner [6].
Despite all this evolution, current knowledge
has been insufficient to assure immutability to
certain practices. Moore et al. have proposed
that nonsteroidal anti-inflammatory drugs
(NSAIDs) be given in the fasting state owing to
its improved pharmacokinetic advantage [4].
Even though this is in accordance to what has
been known for ages in pharmacokinetic terms,
it does not correspond to what has been
proposed for gastroduodenal adverse effects’
sake—it is generally accepted that NSAIDs
should be administered in the fed state. If an
increase in efficiency is paralleled with a
reduction in dosing and this latter fact means
a reduced risk of gastrointestinal issues, then
NSAIDs administration in the fasting state
ought to be seriously considered.
This simple shift in paradigm comes to
exemplify the major importance of being
attentive to the outcomes of our practice,
which should make us strive for integration of
each and every single piece of clinical
information. Whether patient A coped well
with drug X, patient B had no improvement
with drug Y or patient C reported certain side
effects with drug Z, all these individual pieces of
information should be compiled into some
common database of medical records where
these variables can be collectively appreciated.
Furthermore, a tool to estimate the probability
of an adverse drug reaction like the ten-item
algorithm from Naranjo et al. [7] should also be
incorporated. Such a data repository can derive
from practice-based research networks, which
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can indeed provide invaluable
pharmacoepidemiological information [2, 8].
In order to comply with principles of good
clinical practice, such data repository must not
include individual pieces of information that
could identify patients (e.g., name, detailed
address, identification card number, etc.).
Only variables of medical interest, including
those that may be of help in spotting protective
or risk features for treatment response or
complications, are warranted. The
development of such record at a nationwide
level would compete with large-scale
observational studies at incredibly lower costs.
The infrastructure of practice-based research
networks would also be advantageous to both
patients and pharmaceutical companies as it
would accelerate the detection of safety issues
unidentified at earlier stages of development as
well as anticipate assessment of efficacy in a
relatively controlled environment.
This central data repository should not
receive inputs only from health professionals.
Electronic health records (EHR) are an
opportunity to put into practice a proactive
approach to medical information collection,
not only reminding doctors to assess the
effects of prescriptions at a later appointment
but also by acquiring data directly at the patient
level, promoting empowerment and
responsibility among patients and carers [9].
This would truly be a person-centric approach
to health care and research [2].
Practice-based research networks can bring
further advantage by promoting detection and
reporting of medical errors. Medical incidents
and adverse events in primary care/general
practice are erroneously at a very low level
[10]. This is probably a consequence of both
ineffective reporting mechanisms and
fragmented levels of information. Without a
major focus on quality assessment and safety
incidents reporting, the opportunity to improve
practices will be postponed until key messages
are made clear by other sources of evidence. The
amount of time we are willing to wait for these
feedback mechanisms to be fully operational
depends entirely on us, health care
professionals. Indeed, a considerable amount
of effort has been dedicated to patient safety for
decades now. However, we believe that further
individual adherence to incident reporting will
only be achieved with promotion of an effective
nationwide EHR. We should urge national and
international health authorities to put forward
legal requirements on feedback mechanisms of
medical practice.
Despite scientific reasoning, nature reaffirms
its complexity by proving medical knowledge
imperfect once again. Against all odds, and after
such a long experience with its prescription, we
are close to changing the paradigm of NSAIDs’
prescription. This should engage the medical
community in a nationwide project of
integrating clinical practice data for
epidemiological purposes. Such an effort of
reporting would be of substantial relevance to
both patient safety and clinical governance
issues. And not only would current use drugs
benefit from an improved surveillance system,
but also brand new medicines, biological
products, and medical devices in general.
Indeed, the Sentinel Initiative by the United
States’ Food and Drug Administration was
established with this same goal. This
programme was devised after the foundation
of FDA’s Critical Path Initiative in 2004 with the
publication of the landmark report Innovation/
Stagnation: Challenge and Opportunity on the
Critical Path to New Medical Products, which
raised concerns and proposed solutions for the
growing crisis in moving basic discoveries to the
market [11]. This document was followed by the
Critical Path Opportunities List, which identified
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specific activities that could improve the
accuracy of tests that predict the safety and
efficacy of potential medical products [12].
Such initiatives and supporting technologies
are making it possible to implement
cutting-edge information systems critical to
fostering public health safety. An example of
this is the Mini-Sentinel safety pilot program,
the pioneer project towards a nationwide
rapid-response electronic safety surveillance
system for drugs and other medical products
[13]. As of the first trimester of 2014, it already
included over 30 collaborating healthcare
institutions, nearly 100 million patients, 2.4
billion medical encounters, and 2.9 billion
prescription drug dispensings [14]. An
endeavor of such magnitude will be retrieving
precious information from everyday clinical
data that will complement existing systems
already in place to track reports of adverse
events linked to the use of regulated products.
However, stakeholders ought not to be
shortsighted and it is imperative that long-run
projects are devised. Nationwide electronic
health records and updated metrics for health
outcomes must be put in place so that
practitioners are captivated to use them.
According to each type of prescription made
or diagnosis coded, a pop-up menu should
allow the physician (or the patient him/
herself) to introduce data such as an
international prostate symptom score in men
with low-urinary tract symptoms, a modified
medical research council score for dyspnea in
chronic obstructive pulmonary disease patients,
a score for any of the available pain assessment
scales for patients with pain, a patient health
questionnaire score for depressive mood
patients or several other state-of-the-art
metrics. This could be driven by an intrinsic
clinical utility deriving from several different
aspects: prescription guidelines often use
quantified data that can be integrated and
analyzed by input data and used to create
alerts and recommendations. There are
innumerous examples of these advantages,
and we elaborate further on only two:
low-density lipoprotein cholesterol levels can
be easily calculated from inputted total
cholesterol, high-density lipoprotein and
triglyceride levels, as well as a cardiovascular
risk score estimated, and both used for sorting
an adequate pharmacologic treatment option.
Several electronic health systems allow for input
of data, calculation of risk and suggesting
treatment options, but none of them propose
treatment options based on the comparison of
individual features (like age, gender, weight,
height, previous response to other drugs) to a
real-time collecting data system. Another
example can be derived from sleep complaints.
The several therapeutic options can be daunting
and a more sound decision can be made if a clue
to the tolerability to trazodone, mirtazapine or
melatonin, for example, can be anticipated
(which is intimately dependent on the liver
microsomal metabolic profile). Therefore,
clinical usefulness would be by itself the major
driving force for incorporating individual
tolerability data into the already busy clinical
workflow. The aim for the extra effort needed
for this task must come from the direct
and indirect clinical utility of the information,
and research gains are derived from a
better-informed medical practice.
Moreover, even in the case of screening tools
that are not evidence-based for clinical use,
performing a clinical trial with such a reporting
system in place would reduce costs and provide
important clinical data in a much shorter time
frame when compared to current research
networks.
Nine active surveillance systems throughout
the world have been described as aiming to
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generate post-marketing drug safety information
[15]. Only one of these is active in the European
Union and none is active in Portugal, at the
present time. The European Union—Adverse
Drug Reaction Alliance has emerged as a
collaborative framework for drug safety studies,
but is still far fromusing real-time data to provide
therapeutic advice to practitioners. This should
be the aim of congregated effort bridging
political, health care and patient stakeholders,
in the best of patient’s interests.
This kind of proposal exemplifies the type of
value-based contribution that can only be made
by physicians and that is the type of leadership
and engagement that can be worthwhile and
cost-saving and has the potential to transform
health care delivery. Such a value-based system
is to be grounded in three fundamental
principles: (1) the goal is value for patients, (2)
health care delivery is organized around
medical conditions and care cycles, and (3)
results are measured [16]. This is not to be found
only in dreaming or wishful thinking but can be
legitimately pursued and accomplished in less
than a decade.
This article does not contain any new studies
with human or animal subjects performed by
any of the authors.
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